Arbutus Q2 revenue $4.7M, net loss $17.1M; AB-101 clears NZ regulatory for Phase 1

Arbutus Biopharma Corp

2023-Q2 EPS reported -$0.20 revenue$11,338,000

Total revenue $4.7M vs $14.2M YoY on lower Qilu license revenue; net loss $17.1M ($0.10 EPS).
Cash $163.5M; runway into Q1 2025; net cash burn guidance $90-95M for 2023.
AB-729 (imdusiran) Phase 2a data at EASL: mean HBsAg decline ~1.6 log10; four patients reached below LLOQ.
AB-101 (oral PD-L1) received NZ Medsafe approval for Phase 1 after FDA clinical hold; dosing starts Q3 2023.
Melissa Rewolinski appointed to board; Karen Sims promoted to CMO; Christopher Naftzger named GC and CCO.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arbutus Biopharma Corp reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 3, 2023, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Arbutus Biopharma Corp filing history →

Source: SEC EDGAR

accession 0001171843-23-004945

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.